IP Library › Granted Patent US 10,066,214
Granted Patent B2
US 10,066,214 · App. 14/898,083 · Granted Sep 4, 2018

Compositions and methods for enhancing virus replication

Inventors: Carolina Solange Ilkow (Ottawa, CA); Fabrice Le Boeuf (Gatineau, CA); John Cameron Bell (Ottawa, CA); Jean-Simon Diallo (Ottawa, CA); Rozanne Arulanandam (Orleans, CA)
Assignee: Turnstone Limited Partnership
C12N7/00A61K35/76A61K35/766A61K35/768A61K38/1793A61K38/1825C07K14/50C07K2319/02C12N2710/16651C12N2710/24151C12N2720/12051C12N2760/16151C12N2760/16152C12N2760/18451C12N2760/18452C12N2760/20232C12N2760/20251
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,066,214
App. No.
14/898,083
Granted
Sep 4, 2018
Kind
B2
Abstract

Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.

Claims (15)

1. An isolated oncolytic virus particle having a genome comprising an open reading frame that encodes FGF2 protein or a functional variant thereof, and an open reading frame that encodes a Type 1 interferon scavenger.

2. The isolated oncolytic virus particle according to claim 1 , wherein the FGF2 protein comprises an amino acid sequence selected from SEQ ID NOs: 2-13.

3. The isolated oncolytic virus particle according to claim 1 , wherein the Type 1 interferon scavenger is B18R protein.

4. The isolated oncolytic virus particle according to claim 3 , wherein the B18R protein comprises an amino acid sequence according to SEQ ID NO: 15, 16 or 17.

5. The isolated oncolytic virus particle according to claim 1 , wherein the oncolytic virus is a rhabdovirus, a vaccinia virus, or a herpes simplex virus-1.

6. The isolated oncolytic virus particle according to claim 5 wherein the rhabdovirus is vesicular stomatitis virus, VSVΔ51, VSV IFN-β, maraba virus, or MG1 virus.

7. The isolated oncolytic virus particle according to claim 1 , wherein the FGF2 protein comprises an amino acid sequence according to SEQ ID NO: 13.

8. The isolated oncolytic virus particle according to claim 1 , wherein the FGF2 protein comprises an amino acid sequence according to SEQ ID NO: 2.

9. The isolated oncolytic virus particle according to claim 3 , wherein the B18R protein comprises an amino acid sequence according to SEQ ID NO: 15.

10. The isolated oncolytic virus particle according to claim 1 , wherein:

the FGF2 protein comprises an amino acid sequence according to SEQ ID NO: 2;

the genome further comprises an open reading frame that encodes a B18R protein that comprises an amino acid sequence according to SEQ ID NO: 15; and

the oncolytic virus is a rhabdovirus virus.

11. The isolated oncolytic virus particle according to claim 10 , wherein the rhabdovirus is MG1 virus.

12. The isolated oncolytic virus particle according to claim 10 , wherein the rhabdovirus is vesicular stomatitis virus.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2017
From: OTTAWA HOSPITAL RESEARCH INSTITUTE
To: TURNSTONE LIMITED PARTNERSHIP
Reel/Frame 044466/0872 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2016
From: DIALLO, JEAN-SIMON; ARULANANDAM, ROZANNE
To: OTTAWA HOSPITAL RESEARCH INSTITUTE
Reel/Frame 037933/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2016
From: ILKOW, CAROLINA SOLANGE; BELL, JOHN CAMERON; LE BOEUF, FABRICE
To: OTTAWA HOSPITAL RESEARCH INSTITUTE
Reel/Frame 037933/0781 →
Continuity (2)
Provisional Application 61835446 · Jun 14, 2013
Related Publication 20160130563A1 · May 12, 2016